These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34469563)

  • 1. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
    Ahmed SS; Lessa FC; Coradin H; Sánchez J; Carvalho MDG; Soda E; Peña C; Fernández J; Cedano D; Whitney CG; Feris-Iglesias J
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S228-S236. PubMed ID: 34469563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
    Silva-Costa C; Brito MJ; Pinho MD; Friães A; Aguiar SI; Ramirez M; Melo-Cristino J; ;
    Emerg Infect Dis; 2018 Jul; 24(7):1307-1314. PubMed ID: 29912700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany.
    Goettler D; Streng A; Kemmling D; Schoen C; von Kries R; Rose MA; van der Linden M; Liese JG
    Vaccine; 2020 Jan; 38(3):570-577. PubMed ID: 31735502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic.
    Dunn MG; Lessa FC; Sánchez J; Cordero R; Feris-Iglesias J; Cedano D; Carvalho MDG; Fernández J; Feemster KA
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S237-S247. PubMed ID: 34469551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant impact of pneumococcal conjugate vaccination on pediatric parapneumonic effusion: Italy 2006-2018.
    Azzari C; Serranti D; Nieddu F; Moriondo M; Casini A; Lodi L; de Benedictis FM; De Vitis E; Cavone F; Cortimiglia M; Indolfi G; Lombardi E; Carloni I; Cutrera R; Lucenteforte E; Resti M; Ricci S
    Vaccine; 2019 May; 37(20):2704-2711. PubMed ID: 30981627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
    Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.
    Syrogiannopoulos GA; Michoula AN; Tsimitselis G; Vassiou K; Chryssanthopoulou DC; Grivea IN
    Infect Dis (Lond); 2016 Oct; 48(10):749-53. PubMed ID: 27320108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of pneumococcal nasopharyngeal colonization and serotypes circulating in Cameroonian children after the 13-valent pneumococcal conjugate vaccine introduction.
    Njuma Libwea J; Gröndahl-Yli-Hannuksela K; Kobela M; Toropainen M; Nyholm O; Ndombo PK; Koulla-Shiro S; Nohynek H; Nuorti JP; Vuopio J; Palmu AA
    Int J Infect Dis; 2020 Sep; 98():113-120. PubMed ID: 32562849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13-valent pneumococcal conjugate vaccine era.
    Díaz-Conradi A; Hernández S; García-García JJ; Muñoz-Almagro C; Moraga-Llop F; Ciruela P; Izquierdo C; Campins M; de Sevilla MF; González-Peris S; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Soldevila N; Salleras L; Domínguez A
    Pediatr Pulmonol; 2019 May; 54(5):517-524. PubMed ID: 30784235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine.
    Satzke C; Dunne EM; Choummanivong M; Ortika BD; Neal EFG; Pell CL; Nation ML; Fox KK; Nguyen CD; Gould KA; Hinds J; Chanthongthip A; Xeuatvongsa A; Mulholland EK; Sychareun V; Russell FM
    Vaccine; 2019 Jan; 37(2):296-305. PubMed ID: 30502068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continued Vaccine Breakthrough Cases of Serotype 3 Complicated Pneumonia in Vaccinated Children, Portugal (2016-2019).
    Silva-Costa C; Gomes-Silva J; Pinho MD; Friães A; Ramirez M; Melo-Cristino J
    Microbiol Spectr; 2022 Aug; 10(4):e0107722. PubMed ID: 35862941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of 13-pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease in children in the Dominican Republic.
    Tomczyk S; Lessa FC; Sánchez J; Peña C; Fernández J; Gloria Carvalho M; Pimenta F; Cedano D; Whitney CG; Verani JR; Coradin H; Garib Z; De Oliveira LH; Feris-Iglesias J
    BMC Infect Dis; 2018 Apr; 18(1):152. PubMed ID: 29609548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Streptococcus pneumoniae serotype distribution in Vojvodina before the introduction of pneumococcal conjugate vaccines into the National Immunization Program.
    Petrović V; Šeguljev Z; Ristić M; Djekić-Malbaša J; Radosavljević B; Medić D; Mihajlović-Ukropina M; Hadnadjev M; Gajic I; Opavski N
    Srp Arh Celok Lek; 2016; 144(9-10):521-6. PubMed ID: 29653038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010-2018.
    Ousmane S; Kobayashi M; Seidou I; Issaka B; Sharpley S; Farrar JL; Whitney CG; Ouattara M
    Vaccine; 2020 May; 38(23):3922-3929. PubMed ID: 32327220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine.
    Diawara I; Zerouali K; Elmdaghri N; Abid A
    BMC Pediatr; 2017 Apr; 17(1):114. PubMed ID: 28449653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise and fall of pneumococcal serotypes carried in the PCV era.
    Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.